港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

瑞博生物-B

53.200

-2.550-4.57%

成交量：11.27萬

成交額：610.42萬

市值：90.74億

市盈率：-25.33

高：58.000

開：56.500

低：52.650

收：55.750

52周最高：95.800

52周最低：51.200

股本：1.71億

香港流通股本：1.71億

量比：0.80

換手率：0.07%

股息：- -

股息率：- -

每股收益(LYR):-2.100

淨資產收益率：--

總資產收益率：-23.42%

市淨率：-83.69

市盈率(LYR):-25.33

市銷率: 52.94

資料載入中...

總覽公司新聞資訊公告

瑞博生物-B2026年5月股份變動月報，股本維持穩定

瑞博生物宣佈向EMA提交II期臨床試驗申請，其siRNA療法於血栓栓塞性疾病領域再獲進展

瑞博生物-B(06938)提交RBD1119注射液用於治療冠狀動脈疾病的II期臨床試驗申請

瑞博生物－Ｂ(06938)股價下跌5.221%，現價港幣$53.55

阿斯达克财经

【券商聚焦】東吳證券維持瑞博生物-B(06938)「買入」評級指FXI、APOC3等管線積極推進

瑞博生物－Ｂ(06938)股價下跌5.211%，現價港幣$57.3

阿斯达克财经

「2026智通財經夏季路演大會」活動報名中！

智通财经网

瑞博生物宣佈與英矽智能達成戰略合作，加速AI驅動的小干擾RNA藥物研發

瑞博生物-B獲董事會授權擬回購不超過已發行股份10%

瑞博生物與英硅智能達成戰略合作，以AI+ siRNA加速小核酸藥物創新研發

瑞博生物-B(06938)：核心產品VORTOSIRAN完成針對靜脈血栓栓塞適應症的2b期臨床試驗申請遞交

瑞博生物-B4月月報：股本保持穩定，暫無新發行或回購

瑞博與勃林格殷格翰在代謝功能障礙相關脂肪性肝炎siRNA療法項目上取得新突破

港股公告掘金 | 天臣控股附屬與地上鐵簽訂備忘錄擬設合資公司打造香港新能源充電換電網絡首期建10座多功能換電站

瑞博生物-B(06938)與勃林格殷格翰的研發合作達成關鍵里程碑

格隆匯個股放量排行榜 | 5月3日

格隆匯個股放量排行榜 | 5月1日

瑞博生物-B聚焦小核酸創新：2025年收入按年增4.1%，研發投入維持2.80億元

港股異動 | 瑞博生物-B(06938)早盤升逾7% Vortosiran房顫卒中預防IIb期申請成功遞交

瑞博生物-B(06938)：核心產品VORTOSIRAN完成針對SPAF適應症的 2b期臨床試驗申請遞交

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06938/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":53.2,"timestamp":1780646950939,"preClose":55.75,"halted":0,"volume":112664,"delay":0,"changeRate":-0.045739910313901296,"floatShares":170554910,"shares":170554910,"eps":-2.100221,"marketStatus":"休市中","change":-2.55,"latestTime":"06-05 16:09:10","open":56.5,"high":58,"low":52.65,"amount":6104188,"amplitude":0.095964,"askPrice":53.25,"askSize":200,"bidPrice":52.75,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":7,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":55.75,"openAndCloseTimeList":[[1780623000000,1780632000000],[1780635600000,1780646400000]],"volumeRatio":0.8034676384161319,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"-23.42%","roe":"--","lyrEps":-2.100221,"volumeRatio":0.8034676384161319,"shares":170554910,"dividePrice":0,"high":58,"amplitude":0.095964,"preClose":55.75,"low":52.65,"week52Low":51.2,"pbRate":"-83.69","psRate":"52.94","week52High":95.8,"institutionHeld":0,"latestPrice":53.2,"eps":-2.100221,"divideRate":0,"volume":112664,"delay":0,"ttmEps":-1.805,"open":56.5,"prevYearClose":57.97,"prevWeekClose":58.2,"prevMonthClose":58.2,"prevQuarterClose":57.3,"fiveDayClose":58.2,"twentyDayClose":61,"sixtyDayClose":60.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1779465600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-06-05","current":-29.473684,"percent":1,"low":-50.513246,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"high":-28.193848,"avg":-36.155873,"sd":5.853216,"marketCap":9073521212},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212}],"updateTime":1780702598732},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1154233652","title":"瑞博生物-B2026年5月股份變動月報，股本維持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154233652","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154233652?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 17:50","pubTimestamp":1780566654,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年6月4日发布的截至2026年5月31日止月份证券变动月报表显示，其股本结构在本月维持稳定，已发行股份总数仍为170,554,910股，注册股本为人民币170,554,910元，全部为H股，票面价值为人民币1元。截至本月底，库藏股份数量依旧为0。报告期内，瑞博生物-B未进行新增股份发行、未发生回购、注销或库藏股变动，已发行股份数与库藏股份数均无变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104647122","title":"瑞博生物宣佈向EMA提交II期臨床試驗申請，其siRNA療法於血栓栓塞性疾病領域再獲進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1104647122","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104647122?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 10:52","pubTimestamp":1779936731,"startTime":"0","endTime":"0","summary":"瑞博生物-B宣布，已就其在研的siRNA疗法向欧洲药品管理局提交了II期临床试验申请。此举标志着该公司在血栓栓塞性疾病治疗领域的研发进程取得了重要推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638234632","title":"瑞博生物-B(06938)提交RBD1119注射液用於治療冠狀動脈疾病的II期臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2638234632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638234632?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 07:46","pubTimestamp":1779925602,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，已成功向欧洲药品管理局提交本公司自主研发产品RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请。尽管标准治疗已被广泛使用，但即使在最佳化治疗下，稳定型CAD患者仍面临发生血栓事件的较大残余风险。RBD1119注射液为一种新型抗血栓siRNA疗法，能提供有效及持久的血栓防护，同时保持良好的安全性特征，尤其是在出血风险方面。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)提交RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638591069","title":"瑞博生物－Ｂ(06938)股價下跌5.221%，現價港幣$53.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2638591069","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638591069?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 15:45","pubTimestamp":1779781500,"startTime":"0","endTime":"0","summary":"[下跌股]瑞博生物－Ｂ(06938) 股价在下午03:44比前收市价下跌5.221%，现股价为港币$53.55。至目前为止，今日最高价为$57.75，而最低价为$53.55。总成交量为21.851万股，总成交金额为港币$1.203千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605263354/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605263354/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636813365","title":"【券商聚焦】東吳證券維持瑞博生物-B(06938)「買入」評級 指FXI、APOC3等管線積極推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2636813365","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636813365?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 13:53","pubTimestamp":1779256397,"startTime":"0","endTime":"0","summary":"公司聚焦FXI、APOC3等关键靶点管线，肝外递送技术取得多项突破。在研管线中，FXI siRNA已完成IIa期试验，计划开展涵盖房颤及静脉血栓栓塞等适应症的IIb期临床；ApoC3 siRNA已获NMPA批准在中国启动II期临床，全球进度领先；PCSK9 siRNA即将由合作伙伴齐鲁制药启动中国III期临床试验。维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981815","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601555","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636804654","title":"瑞博生物－Ｂ(06938)股價下跌5.211%，現價港幣$57.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2636804654","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636804654?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 11:25","pubTimestamp":1779074700,"startTime":"0","endTime":"0","summary":"[下跌股]瑞博生物－Ｂ(06938) 股价在上午11:25比前收市价下跌5.211%，现股价为港币$57.3。至目前为止，今日最高价为$59.65，而最低价为$57.3。总成交量为3.96万股，总成交金额为港币$232.332万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605183877/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605183877/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"「2026智通財經夏季路演大會」活動報名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636304327?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06636","06682","01907","02670","06051","02655","02675","08299","BK1171","02565","02228","02650","01333","02729","03858","03317","00363","01378","02706","BK1155","00305","02142","02685","06090","HK0001040143.USD","LU0307460666.USD","01300","02726","03881","00650","01021","02411","LU0287142896.SGD","01384","02526","02575","BK1100","LU0314109678.HKD","06938","VXUS","01396","09696","02659","00826","00400","02652","02623","00290","06651","02889"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119656495","title":"瑞博生物宣佈與英矽智能達成戰略合作，加速AI驅動的小干擾RNA藥物研發","url":"https://stock-news.laohu8.com/highlight/detail?id=1119656495","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119656495?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 20:31","pubTimestamp":1778589071,"startTime":"0","endTime":"0","summary":"瑞博生物-B（RIBOLIFE-B）与英矽智能（Insilico Medicine）宣布达成一项战略合作，旨在利用人工智能技术加速小干扰RNA（siRNA）药物的研发进程。此次合作将结合双方在生物技术与人工智能领域的专长，共同探索和开发创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109317054","title":"瑞博生物-B獲董事會授權擬回購不超過已發行股份10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109317054","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109317054?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 17:51","pubTimestamp":1778579519,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于最新公告中披露，将在2026年6月5日召开的股东周年大会上提请特别决议案，授权公司董事于法定期间内回购不超过已发行H股总数的10%。公司H股总数为170,554,910股，若该授权通过，最多回购股数可达17,055,491股。自2026年1月9日公司在香港联合交易所有限公司上市以来，瑞博生物-B股价曾在2026年1月至5月间最高达每股95.80港元、最低报51.20港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B获董事会授权拟回购不超过已发行股份10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634296930","title":"瑞博生物與英硅智能達成戰略合作，以AI+ siRNA加速小核酸藥物創新研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2634296930","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634296930?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 14:17","pubTimestamp":1778566620,"startTime":"0","endTime":"0","summary":"此前，瑞博生物与英硅智能已在智能自主化高通量筛选领域达成合作。本次战略合作升级，将依托瑞博生物在小核酸技术与小核酸药物研发领域深厚的产业积淀和领先开发实力，结合英硅智能新药研发全流程的 AI 技术赋能体系，全方面实现优势互补、深度协同，加速创新小核酸药物的研发进程，解决未满足的临床需求，早日惠及全球患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4957191_ZH57191_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ARTY","BK1161","CHAT","AGIX","06938","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634240264","title":"瑞博生物-B(06938)：核心產品VORTOSIRAN完成針對靜脈血栓栓塞適應症的2b期臨床試驗申請遞交","url":"https://stock-news.laohu8.com/highlight/detail?id=2634240264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634240264?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 17:42","pubTimestamp":1778492557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司核心产品vortosiran 已成功向欧洲药品管理局递交针对静脉血栓栓塞症防治的 2b期临床试验申请。本研究为本公司涵盖多个已规划的针对多种血栓栓塞性心血管适应症的2b期研究的一部分。Vortosiran是全球进展最快的靶向FXI的小核酸药物，及截至本公告日期，该产品已完成针对冠状动脉疾病的欧洲2a期临床试验，且其针对心房颤动的 2b期CTA已于2026年4月向EMA递交。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164440037","title":"瑞博生物-B4月月報：股本保持穩定，暫無新發行或回購","url":"https://stock-news.laohu8.com/highlight/detail?id=1164440037","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164440037?lang=zh_tw&edition=fundamental","pubTime":"2026-05-07 17:11","pubTimestamp":1778145080,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年5月7日发布截至2026年4月30日的股份变动月报。公告显示，公司法定注册股本为人民币170,554,910元，且报告期内未发生任何增减变动。截至2026年4月底，公司已发行的H股数量及库存股数均保持在170,554,910股，无新增发行、购回或注销情况。公司现有2,113,987份尚未行使的股份期权，行使价为每股人民币3.70元。本次公告由联席公司秘书张甦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130624137","title":"瑞博與勃林格殷格翰在代謝功能障礙相關脂肪性肝炎siRNA療法項目上取得新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1130624137","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130624137?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 19:22","pubTimestamp":1778066563,"startTime":"0","endTime":"0","summary":"瑞博生物与跨国药企勃林格殷格翰近日宣布，双方针对代谢功能障碍相关脂肪性肝炎的小干扰RNA治疗项目取得重要阶段性进展。该合作标志着两家公司在肝病创新疗法领域迈出关键一步。此次突破性进展为MASH患者带来了新的治疗希望。siRNA技术通过靶向特定基因表达，有望实现对疾病根源的精准干预。两家公司表示，将继续推进该项目的临床前研究，并计划在符合监管要求的前提下尽快开展人体临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633799379","title":"港股公告掘金 | 天臣控股附屬與地上鐵簽訂備忘錄 擬設合資公司打造香港新能源充電換電網絡 首期建10座多功能換電站","url":"https://stock-news.laohu8.com/highlight/detail?id=2633799379","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633799379?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 09:08","pubTimestamp":1778029695,"startTime":"0","endTime":"0","summary":"重大事项：维立志博-B(09887)：LBL-047优先开发干燥综合征、系统性红斑狼疮和皮肌炎临床适应症歌礼制药-B(01672)将携多个项目数据亮相第33届欧洲肥胖症大会(ECO 2026)瑞博生物-B(06938)与勃林格殷格翰的研发合作达成关键里程碑先声药业(02096)：SIM0613(LRRC15抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书医渡科技(02158)附属成功中","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK4588","HK0000252152.HKD","HK0000252160.HKD","01672","HK0000500386.USD","VXUS","06938","BK1515","000941.SH","BK1574","01201","159875","160640","BK1161","BK4585","399941","BK1116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633768975","title":"瑞博生物-B(06938)與勃林格殷格翰的研發合作達成關鍵里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2633768975","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633768975?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 08:10","pubTimestamp":1778026231,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，与勃林格殷格翰(BI)就肝病(包括代谢功能障碍相关脂肪性肝炎(MASH))开发创新治疗方案的研发合作已达成第三个关键里程碑。MASH是一种严重且进行性的脂肪肝疾病，可导致纤维化、肝硬化、肝衰竭及肝癌，影响全球超过2亿人。尽管其负担日益加重，但目前仍需要能够帮助预防疾病进展及支援肝脏健康的有效药物。通过此次合作，本公司与BI旨在扩大MASH 患者未来潜在治疗选择的管线。该里程碑的达成进一步巩固了本公司作为全球制药公司战略合作伙伴的地位，凸显了其siRNA平台的商业潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)与勃林格殷格翰的研发合作达成关键里程碑","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632604150","title":"格隆匯個股放量排行榜 | 5月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632604150","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632604150?lang=zh_tw&edition=fundamental","pubTime":"2026-05-03 17:30","pubTimestamp":1777800604,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/03173056983654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02676","02655","00709","06110","09999","00133","09903","00168","06821","00558","01347","02489","02579","00189","00363","01765","01429","02443","00650","01211","00178","02408","02595","01833","02637","01643","02583","01458","00148","00800","06938","09927","02516","00659","00981","00568","00780","00909","02656","00019","00259","00220","00719","00880","02276","06979","00815","02687","09990","00501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632158966","title":"格隆匯個股放量排行榜 | 5月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632158966","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632158966?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 17:30","pubTimestamp":1777627804,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/01173056970876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00148","02408","00220","00558","01765","09990","00709","00800","09927","02637","00650","01643","02516","00880","06979","02676","02443","01211","00780","06821","02655","01458","02595","01347","02276","02489","02579","00815","02687","06110","00259","00133","00981","01833","02583","00659","01429","09903","00189","09999","00568","00363","02656","00019","00501","00178","00168","00719","00909","06938"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1124839277","title":"瑞博生物-B聚焦小核酸創新：2025年收入按年增4.1%，研發投入維持2.80億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124839277","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124839277?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 16:44","pubTimestamp":1776415486,"startTime":"0","endTime":"0","summary":"瑞博生物-B在2025年度继续专注于小核酸疗法的技术研发与临床推进，核心管线涵盖心血管、肝病及代谢等领域。全年收入为1.49亿元人民币，同比增长4.1%，主要来自合作协议与技术许可等业务；研发开支保持在2.80亿元人民币，与上年基本持平，显示对新药临床与技术平台的持续投入。报告期内，公司年内亏损2.88亿元人民币，上年同期为2.81亿元人民币；归属于母公司拥有人的亏损为2.78亿元人民币，较上年2.70亿元人民币略有扩大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627472360","title":"港股異動 | 瑞博生物-B(06938)早盤升逾7% Vortosiran房顫卒中預防IIb期申請成功遞交","url":"https://stock-news.laohu8.com/highlight/detail?id=2627472360","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627472360?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 11:29","pubTimestamp":1776223751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B早盘涨超7%，截至发稿，涨6.04%，报72.9港元，成交额1172.61万港元。随着Vortosiran针对冠状动脉疾病的IIa期试验的完成，本次申报将进一步巩固和加强该产品作为全球最快的FXI靶向小核酸药物的领先地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","06938","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627464707","title":"瑞博生物-B(06938)：核心產品VORTOSIRAN完成針對SPAF適應症的 2b期臨床試驗申請遞交","url":"https://stock-news.laohu8.com/highlight/detail?id=2627464707","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627464707?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 08:02","pubTimestamp":1776124949,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司核心产品Vortosiran 已成功向欧洲药品管理局递交针对心房颤动患者卒中预防 的2b期临床试验申请，这是全球首个于心房颤动临床试验中的小干扰核酸 XI凝血因子抑制剂，标志着siRNA药物在抗凝疗法领域临床开发的重要里程碑。本研究为本公司涵盖多个已规划的针对多种血栓栓塞性心血管适应症的2b期研究的一部分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":115,"code":"91000000","status":"200"}]}}